MAP2K7 and melanoma: With the recent introduction of the immune checkpoint inhibitors and selective tyrosine kinase inhibitors, including BRAF and MEK inhibitors, there has been a significant improvement in the progression-free survival (PFS) and overall survival (OS) of patients with melanoma [51,52].